Posted on 11/17/2014 in News, Press Releases
SAN DIEGO, CA
– November 17, 2014
– Pathway Genomics Corporation
, a San Diego-based CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced today that it has partnered with the Prospective Registry of Multiplex Testing (PROMPT), an online registry for patients who have undergone testing for cancer-causing genetic mutations. PROMPT is a recently formed consortium of physicians and scientists at academic centers across the nation, including Memorial Sloan Kettering Cancer Center, Mayo Clinic, Abramson Cancer Center of the University of Pennsylvania, and the Dana-Farber Cancer Institute.
"We are honored to collaborate with the country’s leading cancer experts to help advance the understanding of cancer risk, the genes associated with it, and take steps to end preventable hereditary cancers,” said David Becker, Ph.D., Pathway Genomics’ chief scientific officer.
The goal of the registry is to provide vital data needed to better understand the level of risk associated with and outcomes following testing for “panels” of cancer-associated genes. Key milestones were reached this summer, with the completion of the patient online portal in July and ethical approval in August to begin to patient enrollment on the first phase of the study.
Posted on 11/06/2014 in News, Press Releases
Pathway Genomics announced that world-renowned endocrinologist Dr. Glenn D. Braunstein has joined Pathway Genomics’ medical advisory board. Dr. Braunstein is currently the vice president of clinical innovation, director of the Thyroid Cancer Center and professor of medicine at Cedars-Sinai. For 26 years he served as chair of the Department of Medicine at Cedars-Sinai, and holds the James R. Klinenberg, M.D., Chair in Medicine.
“We are honored to have Dr. Braunstein on our medical advisory board, and we look forward to his expert contributions as we rapidly grow our commercial and research divisions,” said Jim Plante, Pathway Genomics’ founder and CEO. “His vast knowledge and veteran experience in medicine will help us continue to enhance and deliver clinically useful genetic tests to physicians and patients.”
Posted on 10/30/2014 in News, Press Releases
Pathway Genomics announced that its breast cancer risk genetic test, BRCA
True, was included in Inc.
magazine’s Coolest Products of the Inc. 500. The genetic test was ranked in the top 12 products from 5000 companies across the nation. View the full list here
“We are honored to be included among incredibly innovative products and forward-thinking companies,” said Jim Plante, Pathway Genomics’ founder and CEO. “Our mission is to provide the most accurate and actionable genetic testing results to physicians and their patients.”
Posted on 10/20/2014 in News, Press Releases
SAN DIEGO, CA
Revolution Slider Error: Slider with alias slider3 not found.
Maybe you mean: 'slider2' or 'home-mid-icons' or 'high-risk-bcancers' or 'bc-testing-options' or 'ColoTrue_ReflexTable' or 'Colo_Assc_Cancer'
– October 20, 2014
– Pathway Genomics Corporation, a CLIA and CAP accredited clinical laboratory that offers genetic testing services globally, announced it has released a patient app that allows existing patients to view their genetic results on mobile devices, such as smart phones and tablets. The announcement was made at the 64th
Annual Meeting of the American Society of Human Genetics (ASHG) in San Diego, California.
“Pathway’s patient app empowers the individual to view their genetic testing results with a push of a button from their mobile device,” said Jim Plante, Pathway Genomics’ founder and CEO. "Patients can now have their genetic testing results accessible at all times."
Posted on 09/09/2014 in News
September 9, 2014 |
Susan G. Komen, the world's largest breast cancer organization, issued a press release this morning announcing a national partnership agreement with global clinical laboratory Pathway Genomics to fund community breast cancer education and outreach programs in five cities nationwide.
The partnership includes funding for education programs and/or sponsorship of Susan G. Komen Race for the Cure® events in San Diego, Los Angeles, Denver and Seattle, along with funding for grants to reach medically underserved women in Washington, D.C., which has the highest death rate from breast cancer of any city in the United States.